Hummingbird Bioscience
Hummingbird Bioscience
Hummingbird Bioscience
  • About Us
  • Science
    • ADC Platform
    • Antibody Platform
    • Publications
  • Pipeline
    • HMBD-001
    • HMBD-501
  • News
  • Partnering
  • Patients
  • Contact
  • Join Us

    PubPosts-HMBD-001

  • All
  • News
  • Publications & Posters
    • HMBD-001
    • Posters
    • Posters - 2024
    • Publications & Posters

    WCLC 2024: A Phase Ib Study to Evaluate HMBD‑001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD‑001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

    Continue Reading
    • HMBD-001
    • Posters
    • Posters - 2024
    • Publications & Posters

    AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

    Continue Reading
    • HMBD-001
    • Posters
    • Posters - 2023
    • Publications & Posters

    ESMO 2023: A CRUK phase I/IIA, first in human dose‐escalation and expansion trial of HMBD‐001 (an anti‐HER3 antibody) in patients with advanced HER3 positive solid tumours

    HMBD-001 is Hummingbird Bioscience’s proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and…

    Continue Reading
    • HMBD-001
    • Posters
    • Posters - 2023
    • Publications & Posters

    WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

    Continue Reading
    • HMBD-001
    • Posters
    • Posters - 2023
    • Publications & Posters

    AACR 2023: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker selected pre-clinical models of squamous cell carcinomas

    Continue Reading
    • HMBD-001
    • Posters
    • Posters - 2021
    • Publications & Posters

    AACR-NCI-EORTC Virtual International Conference 2021: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1 fusion driven cancers

    Continue Reading
    • HMBD-001
    • Publications
    • Publications – 2020
    • Publications & Posters

    Molecular Cancer Therapeutics, AACR Journals: 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models

    Continue Reading
    • HMBD-002
    • Publications
    • Publications – 2018
    • Publications & Posters

    European Journal of Cancer: A novel humanized anti-HER3 antibody with a unique mechanism of action, demonstrates superior tumor inhibition in multiple tumor models compared to other EGFR family therapies.

    Continue Reading
    • HMBD-001
    • Publications
    • Publications - 2017
    • Publications & Posters

    Cancer Research, Volume 77, Issue 13 Supplement, AACR Journals: HMBD-001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors

    Continue Reading

Hummingbird Bioscience

The Galen
61 Science Park Road, #06-15
Singapore 117525


Hummingbird Bioscience Twitter Hummingbird Bioscience Twitter Hummingbird Bioscience LinkedinHummingbird Bioscience Linkedin Hummingbird Bioscience YouTube Hummingbird Bioscience YouTube
Subscribe to our updates
Registered Company No: 201505192N
PRIVACY POLICY | © 2025 Hummingbird Bioscience
  • About Us
  • Science
    • ADC Platform
    • Antibody Platform
    • Publications
  • Pipeline
    • HMBD-001
    • HMBD-501
  • News
  • Partnering
  • Patients
  • Contact
  • Join Us

What are you looking for?

Subscribe to our updates

    *indicates required

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

    Close